Methylergometrine is an ergot alkaloid uterotonic drug developed in the mid-20th century and widely introduced for clinical use in obstetrics. It is primarily used for the prevention and treatment of postpartum hemorrhage due to uterine atony. Its history is associated with strong uterine contraction effects, making it highly effective in controlling excessive bleeding after childbirth, but also requiring careful medical supervision due to its potent vasoconstrictive properties. Methylergometrine acts on smooth muscle receptors in the uterus and blood vessels, leading to sustained uterine contractions and reduced postpartum bleeding. Over time, its use has been refined through clinical studies and safety monitoring, particularly because of its cardiovascular effects and contraindications in hypertensive disorders.
BRAND NAMES
Methergine – the most widely used and recognized brand for prevention and treatment of postpartum haemorrhage.
MECHANISM OF ACTION
Methylergometrine acts as a potent uterotonic agent by stimulating smooth muscle receptors in the uterus, primarily through partial agonist activity at serotonin (5-HT2) and alpha-adrenergic receptors. This leads to sustained and rhythmic uterine contractions, increased uterine tone, and compression of uterine blood vessels, which helps reduce postpartum bleeding. Its strong vasoconstrictive effects also contribute to its clinical action but can affect systemic blood vessels as well.
PHARMACOKINETICS
Absorption
Methylergometrine is rapidly absorbed after oral, intramuscular, or intravenous administration. Intramuscular injection provides more reliable and sustained plasma levels compared to oral dosing, which may have variable absorption due to first-pass metabolism.
Distribution
It is widely distributed in body tissues, with moderate plasma protein binding. It can cross into uterine tissue effectively, which supports its strong uterotonic activity.
Metabolism
The drug is primarily metabolized in the liver through hydroxylation and other biotransformation pathways involving hepatic enzymes.
Elimination
Methylergometrine is eliminated mainly via bile and feces, with a smaller fraction excreted in urine. Its elimination half-life is relatively short (about 2–3 hours), but its pharmacodynamic effects on uterine muscle persist longer.
PHARMACODYNAMICS
Methylergometrine produces strong and sustained uterine contractions by directly stimulating uterine smooth muscle. It enhances uterine tone and reduces uterine bleeding by compressing blood vessels within the myometrium. Its action involves agonism at serotonin (5-HT2) receptors and partial activation of alpha-adrenergic receptors, leading to both uterine contraction and peripheral vasoconstriction. It is especially effective in the third stage of labor for preventing and controlling postpartum hemorrhage.
ADMINISTRATION
Methylergometrine is administered orally, intramuscularly, or intravenously depending on the clinical situation. Intramuscular administration is commonly used for postpartum hemorrhage prevention, while intravenous use is reserved for emergency situations under strict monitoring due to the risk of rapid hypertension. Oral forms may be used for short-term postpartum uterine contraction support.
DOSAGE AND STRENGTH
Typical adult dosing includes 0.2 mg intramuscularly or orally every 2–4 hours as needed for uterine atony or postpartum hemorrhage prevention. In emergency settings, 0.2 mg IV slowly may be given under careful monitoring. Dosage may be adjusted based on uterine response and clinical condition, and repeated dosing should be done cautiously due to vasoconstrictive effects.
DRUG INTERACTIONS
Methylergometrine interacts with CYP3A4 inhibitors (such as macrolide antibiotics, azole antifungals, and protease inhibitors), which can significantly increase drug levels and risk of severe vasoconstriction and hypertension. Concomitant use with other vasoconstrictors or vasopressors may enhance cardiovascular adverse effects.
FOOD INTERACTIONS
Food does not have a major effect on methylergometrine, although oral absorption may be slightly delayed. It is usually recommended to take it consistently in relation to meals if prescribed orally.
CONTRAINDICATIONS
Methylergometrine is contraindicated in patients with hypertension, preeclampsia, eclampsia, or severe cardiovascular disease due to its strong vasoconstrictive effects. It should also not be used during pregnancy before delivery of the placenta, or in individuals with hypersensitivity to ergot alkaloids.
SIDE EFFECTS
Common side effects include nausea, vomiting, abdominal pain, headache, dizziness, and elevated blood pressure. Less commonly, it may cause chest pain, palpitations, and peripheral vasoconstriction leading to cold extremities. Rare but serious effects include severe hypertension, stroke, or myocardial ischemia.
OVER DOSAGE
Overdose of Methylergometrine is primarily characterized by excessive uterine stimulation and severe vasoconstriction. Clinical features may include marked hypertension, severe headache, nausea, vomiting, abdominal pain, chest pain, palpitations, and dizziness. In more serious cases, it can lead to coronary vasospasm, myocardial ischemia, stroke, or seizures due to intense vascular constriction.
TOXICITY
Toxicity of Methylergometrine is primarily due to excessive vasoconstriction, leading to severe hypertension, seizures, chest pain, and ischemic complications affecting the heart or brain. Overdose may also cause intense uterine contractions and abdominal pain. Management is supportive, focusing on blood pressure control and cardiovascular monitoring, as no specific antidote exists.
